KRd significantly prolonged progression-free survival and improved the MRD negativity rate compared to VRd in newly diagnosed multiple myeloma.
The Isa-VRd quadruplet regimen induced sustained MRD negativity and a strong rate complete response or better in patients with transplant-ineligible, newly diagnosed multiple myeloma (NDMM).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback